/ /

  • linkedin
  • Increase Font
  • Sharebar

    Treating retinochoroiditis caused by toxomoplasis

    Two-year follow up shows benefit of trimethoprim-sulfamethoxazole


    The recurrence rate in the group receiving trimethoprim-sulfamethoxazole was 0 at both 1 year and 2 years. In the placebo group, recurrence occurred in 3 patients at 1 year and 11 patients at 2 years, leading to a recurrence rate of 19.6% in the placebo group, compared with 0% in the medication group. No adverse events occurred.

    “This 2-year follow-up suggests a long-term benefit. Prophylactic treatment may reduce the recurrences of toxoplasmic retinochoroiditis in the long-term period,” Dr. Felix said.

    Recent: Why collaboration is needed between retinal, glaucoma specialists

    When the acute treatment ended and the eye was quiet, Dr. Felix and fellow investigators used trimethoprim-sulfamethoxazole as prophylactic treatment for up to a year after acute treatment.

    More: Gene-based treatment provides sustained AMD therapy


    João Paulo Fernandes Felix, MD

    E: [email protected]

    This article was adapted from Dr. Felix’s presentation at the 2015 meeting of the American Academy of Ophthalmology. Dr. Felix did not indicate any proprietary interest in the subject matter.

    Subscribe Here For Free eNewsletter


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results